目的系统评价XELOXs方案与FOLFOXs方案在治疗进展期胃癌中的疗效及不良反应。方法在万方、维普、CNKI、Pub Med数据库中检索XELOXs和FOLFOXs方案治疗进展期胃癌的前瞻性临床对照试验研究,对纳入研究进行质量评价,采用Rev Man 5.3进行Met...目的系统评价XELOXs方案与FOLFOXs方案在治疗进展期胃癌中的疗效及不良反应。方法在万方、维普、CNKI、Pub Med数据库中检索XELOXs和FOLFOXs方案治疗进展期胃癌的前瞻性临床对照试验研究,对纳入研究进行质量评价,采用Rev Man 5.3进行Meta分析。结果纳入12篇文献,共计825例患者。XELOXs组有效率较FOLFOXs组高(RR=1.18,95%CI:1.04~1.36,P=0.01);XELOXs方案胃肠道反应(RR=0.47,95%CI:0.39~0.57)、血小板减少(RR=0.64,95%CI:0.47~0.87)、腹泻(RR=0.59,95%CI:0.44~0.79)、白细胞减少(RR=0.53,95%CI:0.38~0.75)的发生率较FOLFOXs组低(P<0.05),手足综合症的发生率较FOLFOXs组高(RR=3.22,95%CI:0.90~11.51;P<0.00001)。XELOXs组不同累计治疗量间的疗效差异无统计学意义(P=0.125);高计量组神经毒性(P=0.002)、白细胞减少(P=0.020)、血小板较少(P=0.000)发生率高于其它两组。结论在治疗进展期胃癌中,XELOXs方案疗效优于FOLFOXs方案;XELOXs方案不同累计治疗剂量间疗效无差异,且不良反应发生率随剂量增高而增高。展开更多
AIM To evaluate the efficiency and safety of hepatic artery infusion chemotherapy(HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer(CRC) liver metastasis(CRCLM).METHODS A retrospective analysis of patien...AIM To evaluate the efficiency and safety of hepatic artery infusion chemotherapy(HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer(CRC) liver metastasis(CRCLM).METHODS A retrospective analysis of patients with unresectable CRCLM who failed systemic chemotherapy and were subsequently treated with HAIC at our institute from May 2013 to April 2015 was performed. A total of 24 patients were treated with 5-fluorouracil, and 18 patients were treated with raltitrexed. RESULTS The median survival time(MST) from diagnosis of CRC was 40.8 mo in the oxaliplatin plus raltitrexed(TOMOX) arm and 33.5 mo in the oxaliplatin plus 5-fluorouracil(FOLFOX) arm(P = 0.802). MST from first HAIC was 20.6 mo in the TOMOX arm and 15.4 mo in the FOLFOX arm(P = 0.734). Median progression-free survival(PFS) from first HAIC was 4.9 mo and 6.6 mo, respectively, in the TOMOX arm and FOLFOX arm(P= 0.215). Leukopenia(P = 0.026) was more common in the FOLFOX arm, and hepatic disorder(P = 0.039) was more common in the TOMOX arm. There were no treatment-related deaths in the TOMOX arm and one treatment-related death in the FOLFOX arm. Analysis of prognostic factors indicated that response to HAIC was a significant factor related to survival.CONCLUSION No significant difference in survival was observed between the TOMOX and FOLFOX arms. HAIC treatment with either TOMOX or FOLFOX was demonstrated as an efficient and safe alternative choice.展开更多
文摘目的系统评价XELOXs方案与FOLFOXs方案在治疗进展期胃癌中的疗效及不良反应。方法在万方、维普、CNKI、Pub Med数据库中检索XELOXs和FOLFOXs方案治疗进展期胃癌的前瞻性临床对照试验研究,对纳入研究进行质量评价,采用Rev Man 5.3进行Meta分析。结果纳入12篇文献,共计825例患者。XELOXs组有效率较FOLFOXs组高(RR=1.18,95%CI:1.04~1.36,P=0.01);XELOXs方案胃肠道反应(RR=0.47,95%CI:0.39~0.57)、血小板减少(RR=0.64,95%CI:0.47~0.87)、腹泻(RR=0.59,95%CI:0.44~0.79)、白细胞减少(RR=0.53,95%CI:0.38~0.75)的发生率较FOLFOXs组低(P<0.05),手足综合症的发生率较FOLFOXs组高(RR=3.22,95%CI:0.90~11.51;P<0.00001)。XELOXs组不同累计治疗量间的疗效差异无统计学意义(P=0.125);高计量组神经毒性(P=0.002)、白细胞减少(P=0.020)、血小板较少(P=0.000)发生率高于其它两组。结论在治疗进展期胃癌中,XELOXs方案疗效优于FOLFOXs方案;XELOXs方案不同累计治疗剂量间疗效无差异,且不良反应发生率随剂量增高而增高。
基金Supported by Capital Medical Development and Scientific Research Fund,China,No.2014-2-2154
文摘AIM To evaluate the efficiency and safety of hepatic artery infusion chemotherapy(HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer(CRC) liver metastasis(CRCLM).METHODS A retrospective analysis of patients with unresectable CRCLM who failed systemic chemotherapy and were subsequently treated with HAIC at our institute from May 2013 to April 2015 was performed. A total of 24 patients were treated with 5-fluorouracil, and 18 patients were treated with raltitrexed. RESULTS The median survival time(MST) from diagnosis of CRC was 40.8 mo in the oxaliplatin plus raltitrexed(TOMOX) arm and 33.5 mo in the oxaliplatin plus 5-fluorouracil(FOLFOX) arm(P = 0.802). MST from first HAIC was 20.6 mo in the TOMOX arm and 15.4 mo in the FOLFOX arm(P = 0.734). Median progression-free survival(PFS) from first HAIC was 4.9 mo and 6.6 mo, respectively, in the TOMOX arm and FOLFOX arm(P= 0.215). Leukopenia(P = 0.026) was more common in the FOLFOX arm, and hepatic disorder(P = 0.039) was more common in the TOMOX arm. There were no treatment-related deaths in the TOMOX arm and one treatment-related death in the FOLFOX arm. Analysis of prognostic factors indicated that response to HAIC was a significant factor related to survival.CONCLUSION No significant difference in survival was observed between the TOMOX and FOLFOX arms. HAIC treatment with either TOMOX or FOLFOX was demonstrated as an efficient and safe alternative choice.
